Banner - NPPA Connect

Opinion|Videos|December 5, 2024

Dosing Considerations and Assessing the Efficacy of Treatment

Author(s)Merrick D. Elias, DO, FAAD, Hadar Avihai Lev-Tov, MD, Iltefat Hamzavi, MD

Panelists discuss how artificial intelligence could revolutionize HS diagnosis through automated image analysis, pattern recognition of clinical presentations, and improved early detection capabilities, potentially reducing diagnostic delays.

Episodes in this series

3 experts in this video

EP. 1 Burden of Hidradenitis Suppurativa on Patients and Diagnostic Challenges

3 experts in this video

EP. 2 Efficacy and Safety of Current Treatments for HS

3 experts in this video

EP. 3 Future Innovations for HS Diagnosis and Management

3 experts in this video

EP. 4 Dosing Considerations and Assessing the Efficacy of Treatment

3 experts in this video

EP. 5 Potential Role of AI in HS Diagnosis

2 experts in this video

EP. 6 Early Recognition and Use of Biologics to Manage Hidradenitis Suppurativa

2 experts in this video

EP. 7 Setting Patient Expectations and Use of Combination Treatment for Hidradenitis Suppurativa

2 experts in this video

EP. 8 Treatment Switches and the Future of Hidradenitis Suppurativa Management

EP. 9 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 1

EP. 9 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 1

EP. 10 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 2

EP. 10 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 2

EP. 11 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 3

EP. 11 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 3

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Trending on Dermatology Times

Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension

Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease

Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine

Case Report Highlights Rural Care Gaps in Recurrent Merkel Cell Carcinoma

Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial